ACR is now undervalued, IMO.
OBJ is valued at similar of ACR's. Mr Market always overacts bad news.
High volumes during last three days, suggest it may have a big movement ahead. ACR is still under ASX200, where instos can make money by shorting or going long.
Net cash around $34m ATM, my estimats. Also, the US$50m milstone payment is not entirely gone, likely just deferred one year as announced. give enterprise value around $80m, for a bio company that already has a product on sale.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
-0.001(5.26%) |
Mkt cap ! $7.339M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $11.58K | 619.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 335415 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 516258 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |